These challenges, in part, have led to 8 of the 10 largest healthcare shares<\/a>\u00a0on the market trading at or close to multi-year lows<\/a>.<\/p>\n This week on The Bull<\/a>, analysts reveal buy ratings on three ASX 200 healthcare shares, and why they see value in them today.<\/p>\n Image source: Getty Images<\/p>\n Pro Medicus Ltd (ASX: PME<\/a>) <\/p>\n The Pro Medicus share price is $124.94, up 0.8% on Thursday.<\/p>\n This ASX 200\u00a0healthcare\u00a0share has dropped 60% over six months, and hit a two-year low of $107.75 in late February. <\/p>\n Blake Halligan from Catapult Wealth has a buy recommendation on Pro Medicus shares.<\/p>\n Halligan explains: <\/p>\n With an underlying earnings before interest and tax margin at 73 per cent and cash of $222 million, PME remains financially robust. <\/p>\n Growing US market share supports a positive long term growth outlook, making PME an attractive portfolio addition.<\/p>\n Telix Pharmaceuticals Ltd (ASX: TLX<\/a>) <\/p>\n The Telix Pharmaceuticals\u00a0share price is $13.29, up 0.7% today.<\/p>\n This ASX 200\u00a0healthcare\u00a0share has fallen by 14% over six months and by 48% over the past year.<\/p>\n The stock hit a two-year low of $8.26 in February.<\/p>\n Mark Gardner from MPC Markets says Telix Pharmaceuticals shares are a buy, commenting:<\/p>\n The company recently re-submitted its drug application to the US Food and Drug Administration (FDA) for Pixclara, an imaging agent for a particularly aggressive form of brain cancer. <\/p>\n The FDA has given it priority status, and Telix has gone through a formal meeting to address every question raised in its previous application. In our view, a re-submission isn’t a setback, but the last step before approval. <\/p>\n We believe the market isn’t pricing in the benefits of a potentially successful FDA outcome.<\/p>\n![\"Five](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/04\/healthcare-workers-3-16.9-1200x675.jpg\")
<\/p>\n